Currently out of the existing stock ratings of Stan Berenshteyn, 27 are a BUY (42.19%), 5 are a SELL (7.81%), 32 are a HOLD (50%).

Stan Berenshteyn

Work Performance Price Targets & Ratings Chart

Analyst Stan Berenshteyn, currently employed at WELLS FARGO, carries an average stock price target met ratio of 65.36% that have a potential upside of 17.94% achieved within 142 days.

Stan Berenshteyn’s has documented 129 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GDRX, Goodrx Holdings at 28-Feb-2025.

Wall Street Analyst Stan Berenshteyn

Analyst best performing recommendations are on ACCD (ACCOLADE ).
The best stock recommendation documented was for GDRX (GOODRX HOLDINGS ) at 8/10/2023. The price target of $7 was fulfilled within 7 days with a profit of $1.25 (15.15%) receiving and performance score of 21.65.

Average potential price target upside

of $27.62 (38.6%) on HQY (HEALTHEQUITY).
of $22.09 (11.25%) on VEEV (VEEVA SYSTEMS).
of $7.26 (24.35%) on DOCS (DOXIMITY).

OMCL Omnicell ACCD Accolade GDRX Goodrx Holdings HQY HealthEquity DOCS Doximity HCAT Health Catalyst TDOC Teladoc VEEV Veeva Systems AMWL American Well Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Anne Samuel (JPMORGAN)